CKD classification | No events/no at risk | P-years | Rate/1000 p-years | Model 1 | Model 2 | Model 3 |
|---|
HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P |
|---|
CKD stage |
 No CKD | 61/5703 | 27414.3 | 2.2 (1.7–2.9) | 1 (reference) | … | 1 (reference) | … | 1 (reference) |  |
 CKD G1 | 27/1218 | 5701.1 | 4.7 (3.2–6.9) | 2.27 (1.44–3.59) | < 0.001 | 1.76 (1.10–2.83) | 0.019 | 1.76 (1.10–2.83) | 0.020 |
 CKD G2 | 35/1290 | 6090.1 | 5.7 (4.1–8.0) | 2.31 (1.51–3.53) | < 0.001 | 1.79 (1.15–2.79) | 0.010 | 1.77 (1.13–2.75) | 0.012 |
 CKD G3 | 33/959 | 4719.5 | 7.0 (5.0–9.8) | 2.57 (1.65–4.02) | < 0.001 | 2.09 (1.31–3.33) | 0.002 | 2.03 (1.27–3.24) | 0.003 |
CKD risk categories |
 Low risk | 61/5703 | 27414.3 | 2.2 (1.7–2.9) | 1 (reference) | … | 1 (reference) | … | 1 (reference) |  |
 Moderate risk | 52/2484 | 11876.6 | 4.4 (3.3–5.7) | 1.84 (1.27–2.68) | 0.001 | 1.56 (1.06–2.29) | 0.023 | 1.55 (1.05–2.27) | 0.026 |
 High risk | 33/797 | 3719.8 | 8.9 (6.3–12.5) | 3.62 (2.35–5.57) | < 0.001 | 2.62 (1.65–4.16) | < 0.001 | 2.56 (1.61–4.07) | < 0.001 |
 Very high risk | 10/186 | 914.4 | 10.9 (5.9–20.3) | 4.22 (2.14–8.32) | < 0.001 | 2.95 (1.46–5.96) | 0.003 | 2.86 (1.41–5.80) | 0.004 |
- CKD was classified according to the KDIGO clinical practice guidelines as follows: (1) no CKD defined as eGFR ≥ 60 and UACR < 30; (2) CKD G1, as eGFR ≥ 90 and UACR ≥ 30; (3) CKD G2, as eGFR between 60 and 89 and UACR ≥ 30; (4) CKD G3, as eGFR between 30 and 59 regardless of UACR
- CKD risk categories were defined by eGFR and UACR as follows: (1) low risk, as eGFR ≥ 60 and UACR < 30; (2) moderate risk, as (45 ≤ eGFR < 60 and UACR < 30) or (eGFR ≥ 60 and 30 ≤ UACR ≤ 300); (3) high risk, as (30 ≤ eGFR < 44 and UACR < 30) or (45 ≤ eGFR < 60 and 30 ≤ UACR ≤ 300) or (eGFR ≥ 60 and UACR > 300); (4) very high risk, as (30 ≤ eGFR < 44 and 30 ≤ UACR ≤ 300) or (30 ≤ eGFR < 60 and UACR> 300)
- Model 1 adjusted for age, sex, race, and treatment arm; model 2, model 1 variables plus duration of diabetes, hemoglobin A1C, cigarette smoking, alcohol intake; body mass index, total-to-HDL cholesterol, systolic BP, use of BP-lowering medications, atrial fibrillation; history of CVD (excluding stroke) at baseline; model 3, model 2 variables plus use of antiplatelet agents (including aspirin)/ anticoagulants, diuretics, ACEI/ARB.
- ACEI indicates angiotensin-converting enzyme inhibitors, ARB angiotensin-II receptor blockers, BP blood pressure, CKD chronic kidney disease, CI confidence interval, CVD cardiovascular disease, eGFR estimated glomerular filtration rate, HDL high-density lipoprotein, HR hazard ratio, KDIGO Kidney Disease: Improving Global Outcomes, p-years person-years, UACR urine albumin-creatinine ratio
